Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 434.53M | 419.81M | 356.30M | 280.91M | 213.23M | 148.68M |
Gross Profit | 288.06M | 284.88M | 232.29M | 171.64M | 131.84M | 96.29M |
EBITDA | -9.16M | -25.58M | -104.00M | -145.48M | -92.30M | -7.62M |
Net Income | -42.72M | -58.53M | -136.88M | -176.15M | -118.16M | -27.29M |
Balance Sheet | ||||||
Total Assets | 400.39M | 388.42M | 370.33M | 370.06M | 494.48M | 326.67M |
Cash, Cash Equivalents and Short-Term Investments | 90.87M | 84.22M | 87.52M | 176.68M | 313.81M | 218.78M |
Total Debt | 15.87M | 17.80M | 11.98M | 9.18M | 15.80M | 14.32M |
Total Liabilities | 118.21M | 123.61M | 118.88M | 82.24M | 77.20M | 63.36M |
Stockholders Equity | 282.19M | 264.81M | 251.45M | 287.82M | 417.28M | 263.31M |
Cash Flow | ||||||
Free Cash Flow | 25.48M | 8.29M | -57.48M | -116.33M | -105.52M | -15.69M |
Operating Cash Flow | 47.95M | 32.38M | -32.38M | -90.12M | -74.71M | 2.89M |
Investing Cash Flow | -26.04M | -24.09M | -39.67M | -26.20M | -65.23M | -25.09M |
Financing Cash Flow | -10.50M | -11.49M | -17.11M | -20.41M | 234.97M | 150.66M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
71 Outperform | $1.70B | ― | -15.97% | ― | 16.29% | 66.01% | |
59 Neutral | $1.51B | ― | -43.33% | ― | 22.29% | -32.89% | |
51 Neutral | $7.41B | 0.36 | -61.88% | 2.33% | 17.09% | 1.64% | |
45 Neutral | $1.03B | ― | -16.71% | ― | -2.50% | -30760.27% | |
42 Neutral | $1.44B | ― | -69.30% | ― | ― | -68.13% | |
$2.20B | ― | -3.37% | ― | ― | ― | ||
51 Neutral | $1.64B | ― | -70.58% | ― | 100.03% | 64.22% |
On June 25, 2025, Phreesia, Inc. held its annual stockholders’ meeting where three proposals were voted on. The stockholders elected two directors, Gillian Munson and Mark Smith, M.D., for a three-year term. Additionally, the appointment of KPMG LLP as the independent registered public accounting firm was ratified, and the compensation of named executive officers was approved on a non-binding, advisory basis.
The most recent analyst rating on (PHR) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Phreesia stock, see the PHR Stock Forecast page.